Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Thaler

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Wiener Klinische Wochenschrift|March 3, 2012
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]Ingrid Pabinger, Günther Gastl, Michael Steurer, et al.
Annals of Hematology|June 22, 2014
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Sonja Burgstaller, Michael Girschikofsky, et al.
JAMA Oncology|November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational StatusJulien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Journal of Hematology & Oncology|April 17, 2016
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsLisa Pleyer, Sonja Burgstaller, Reinhard Stauder, et al.
Communications Biology|May 24, 2020
IDO1<sup>+</sup> Paneth cells promote immune escape of colorectal cancerSandra Pflügler, Jasmin Svinka, Irene Scharf, et al.
European Journal of Haematology|May 17, 2021
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaSigrid Machherndl-Spandl, Eva Jäger, Agnes Barna, et al.
International Journal of Molecular Sciences|February 18, 2017
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Hartmut Döhner, Hervé Dombret, et al.
Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Wiener Klinische Wochenschrift|March 3, 2012
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)]Ingrid Pabinger, Günther Gastl, Michael Steurer, et al.
Annals of Hematology|June 22, 2014
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Sonja Burgstaller, Michael Girschikofsky, et al.
JAMA Oncology|November 24, 2017
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational StatusJulien Taieb, Hampig Raphael Kourie, Jean-François Emile, et al.
American Journal of Hematology|December 30, 2014
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2bNicole C C Them, Klaudia Bagienski, Tiina Berg, et al.
Journal of Hematology & Oncology|April 17, 2016
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsLisa Pleyer, Sonja Burgstaller, Reinhard Stauder, et al.
Communications Biology|May 24, 2020
IDO1<sup>+</sup> Paneth cells promote immune escape of colorectal cancerSandra Pflügler, Jasmin Svinka, Irene Scharf, et al.
European Journal of Haematology|May 17, 2021
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemiaSigrid Machherndl-Spandl, Eva Jäger, Agnes Barna, et al.
International Journal of Molecular Sciences|February 18, 2017
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Hartmut Döhner, Hervé Dombret, et al.
Haematologica|May 20, 2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinibStein-Erik Gullaksen, Jørn Skavland, Sonia Gavasso, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
Pageof 8